TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in mean Probing Depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic floor knowledge scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: AUC of the MonoMark test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of 28 day survival
Endpoint domain: Mortality/survival
Primary endpoint: rate of patients returning to the previous living situation
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Adipose lipolysis and triglyceride turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Uptake of radiopharmaceutical in breast tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Bone Formation Rate (BFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of subjects achieving mean serum phosphorus levels above the LLN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Perceived Usability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility (Participation Rate)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Assessment of Radial Pressure Pulse-wave
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Electroencephalogram analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visual analogue scale for axial pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Decrease in Parasite prevalence according to RDT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Decrease in Parasite prevalence according to PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total and confirmed outpatient (OPD) malaria case incidence and inpatient (IPD) malaria case incidence among all ages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of TAXUS stent related cardiac events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Behavior Change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline in Blood Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete and near complete response rate (CR/nCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients maintaining plasma HIV viral load < 400 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sick leave
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: recovery time after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause postoperative mortality
Endpoint domain: Mortality/survival
Primary endpoint: Citrate clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean difference in FLT uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beta activity (15-35 Hz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in self-reported alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface Luster
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color Stability and Translucency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anatomic Form
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time frame between diagnosis and access to oncologies care facilities
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in coronary atheroma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline Systolic and Diastolic pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Constriction Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Dilation Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pupil Constriction Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Modified United States Public Health Services (USPHS) criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful elimination of infestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total traced vitamin A mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Recovery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain as Assessed by Numeric Pain Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical examinations, vital signs, and ECGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change of BCVA from baseline at 12 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change of BCVA from baseline at 48 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in preference score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasmatic prasugrel metabolites concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose Limiting Toxicity Rate (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Remission Rate (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Change in VAS
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Mean Change in ODI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in [C-11]flumazenil distribution volume (VT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Levels of ocrelizumab in breastmilk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to peak levels of ocrelizumab in breastmilk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of erlotinib hydrochloride
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in C-peptide kinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in scores on the Oxford Measure of Psychosocial Adjustment & WHODAS 2.0
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in scores on the Youth Assessment Battery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Hamilton Depression Rating Scale (HAM-D 17) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reported Side Effects Based on PRISE AE Scores
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of CAM use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: angiographic binary re-restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Changes from baseline ANU-ADRI
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: abdominal symptom outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: clinical cure of clostridioides difficile infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of participants with ≥ 30% reduction in iPTH level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Anxiety elicited during EGD
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity and specificity of lung sonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Panel reactive antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving a Meningococcal C Serum Bactericidal Assay (SBA) Titer ≥1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b (Hib) PRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Treatment-Related Symptoms of Post Traumatic Stress
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of Synovial Lymphocytic Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Degree of Cartilage Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Degree of Bony Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Postoperative 24hr morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic failure death or intubation
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients responding to albuterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of Confirmed Relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of eGFR by MDRD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in proteinuria (Microalbuminuria)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to the development of end-stage renal disease (ESRD)/Hemodialysis
Endpoint domain: Mortality/survival
Primary endpoint: Significant finger-specific activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in vision-guided mobility assessment (VMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Ocular and Non-ocular Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Abnormalities in Laboratory Assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Width of the Metatarsal Heads (Minimal Detectable Change [MDC])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Width of the Calcaneus (Minimal Detectable Change [MDC])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot Length (Minimal Detectable Change [MDC])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve of digoxin from zero hours to infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CLr (Renal clearance) of digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: CL/F (Apparent clearance following oral dosing) of digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peyronie's Disease Questionnaire (PDQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hip and Knee Decision Quality Instruments Knowledge Subscale Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fear-potentiated startle reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with Intensive care unit admission and orientation processes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient satisfaction with physical care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient satisfaction with psychological care
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient satisfaction with social interaction
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Patient satisfaction with health teaching
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient satisfaction with maintaining a safe healing environment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Atrial Fibrillation Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bone Metastasis-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Major pathological regression (MPR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy as per investigator global assessment (IGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Length of Utterances (MLU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquisition of noun-verb and color-shape combinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergence of intraverbal responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of CASA-Q score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Women Who Test Ethyl Glucuronide (EtG) Negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain on the visual analog scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients stopped convulsing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total duration of HDM SLIT prescription planned by the physician
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hospitalizations and emergency visits for heart failure
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Patients With Grade 3 and Grade 4 Possibly-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic accuracy to identify atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Summed Pain Intensity Difference (SPID)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Kidney Injury (AKI) Knowledge Assessment score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean Expiratory Airflow During Comfortable Phonation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Voicing Efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in body appreciation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in body functionality appreciation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to Reach a 4 Point Increase in UPDRS Motor Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Levodopa Equivalents, Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Resulting in Negative Biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Neglect Test (NET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak lactate/pyruvate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak bicarbonate/pyruvate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Standard Complication Questionnaire
Endpoint domain: Adverse events/effects
Primary endpoint: MS Impact Scale - MSIS-29
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Modified SF-36 Cell-Based Therapy Follow Up
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Physical Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4+ T lymphocytes counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Major amputation of the index limb
Endpoint domain: Mortality/survival
Primary endpoint: Persisting, unchanged critical limb ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Beliefs about medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With an AMD Event
Endpoint domain: Adverse events/effects
Primary endpoint: Survival of the restorations
Endpoint domain: Mortality/survival
Primary endpoint: Success of the restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multidimensional Pain Inventory (MPI) score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Total Inflammatory Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remaining astigmatism (in Diopters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal Staining of Grade 3 or 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of the device assessed through Buttocks Evaluation Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Who Were Insulin Independent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Deep remission maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: growth in substance use
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: growth in antisocial behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: growth in deviant peer involvement
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Cleveland Clinic Incontinence Score (CCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: St. Mark's incontinence score (Vaizey score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24-hour Average Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pittsburgh Sleep Quality Index (PSQI) Score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of Participants With PSS Score Indicating Low Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of TE-SAE (Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade, Ventricular Arrhythmias)
Endpoint domain: Mortality/survival
Primary endpoint: Change in mobility score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: expression rate of TNF-alpha in biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sniffin Stick test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of articaine local infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of emergence delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of post-procedure amenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Brain electrical impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of Oraxol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composite major complications
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Early Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Late Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Weeks of abstinence
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Pupillary threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean wheal diameter of SPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tampa Kinesiophobia Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of Accurate High Confidence Polyp Histology Predictions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numerical Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission and response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validation of psCAM-ICU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of post-transplant cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Mean T-score of Visual Analogue Mood Scales (VAMS) Angry State
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing